The core function of the Screening Group (SCR) at IARC is to provide data on the accuracy, reproducibility, efficacy, benefits, harmful effects, and cost-effectiveness of various early detection interventions for breast, cervical, colorectal, and oral cancers, among others, in reducing deaths and improving patients’ quality of life in various settings. These data can then be used to inform and improve the rational use of health-care resources. The Group’s ultimate objective is to guide the development of public health policies for implementing screening in a variety of health-care settings, in particular in low- and middle-income countries (LMICs).
SCR conducts field studies in LMICs to evaluate various early detection methods for breast, cervical, colorectal, and oral cancer control. These initiatives also address the means by which screening services could be scaled up through local public health services. SCR develops various training resources to catalyse and augment capacity building in close collaboration with national institutions and government health services. Through its research programme, SCR generates scientific evidence to support the development of resource-appropriate early detection policies and health systems for the delivery of effective early services. For example, the Group significantly contributed to the evaluation of the safety and efficacy of less than three doses of the HPV vaccine in protecting against cervical cancer.
New publication: “Increasing risk of uterine cervical cancer among young Japanese women: Comparison of incidence trends in Japan, South Korea and Japanese-Americans between 1985 and 2012.”26/03/2019
Our Group and collaborators recently published a paper about the increasing incidence of cervical cancer in young Japanese women. This trend was not observed among Japanese-American and South Korean women, for the same period of time (1985-2012). These findings are likely to be attributable to increasing prevalence of human papillomavirus (HPV) infection among young women, and they emphasize urgent need for effective cancer control programs including resuming pro-active recommendation of the HPV vaccination and improving cervical cancer screening in Japan. View the article.
Video IARC International Women’s Day Symposium: Walking towards light25/03/2019
Professor Ashrafun Nessa, Bangabandhu Sheikh Mujib Medical University Hospital, Bangladesh, has been the focal point of the Cervical and Breast Cancer Screening Programme of the Government of Bangladesh since 2004, helping to develop screening and colposcopy clinics with support of the Screening Group.
Training course on the role of low-cost portable magnifying device and colposcopy in the early detection and prevention of cervical cancer, Lusaka, Zambia18/03/2019 – 23/03/2019
Dr Partha Basu and Dr Srabani Mittal conducted this practical training course to train the trainers within the framework of the project “Diagnostic test accuracy of the low-cost portable magnifying device mobile colposcope in HIV-positive women in Zambia” in collaboration with the Department of Reproductive, Maternal, Newborn, and Child Health at the Centre for Infectious Disease Research in Zambia (CIDRZ), and the Institute of Social and Preventive Medicine (ISPM), Switzerland.
|Gadgil A., Sauvaget C., Roy N., Muwonge R., Lucas E., Sankaranarayanan R. Setting up a Breast Cancer Awareness Project in Mumbai: Methodology, Experiences and Challenges. J Cancer Educ. 2019 Mar 12. doi: 10.1007/s13187-019-01500-x.|
|Randall T.C., Sauvaget C., Muwonge R., Trimble E.L., Jeronimo J. Authors response to Papoutsis and colleagues letter to the editor regarding: Worthy of further consideration: An updated meta-analysis to address the feasibility, acceptability, safety and efficacy of thermal ablation in the treatment of cervical cancer precursor lesions. Prev Med. 2019 Feb 10.|
|Two-dose recommendation for Human Papillomavirus vaccine can be extended up to 18 years - updated evidence from Indian follow up cohort study. Basu P., Muwonge R., Bhatla N., Nene B.M., Joshi S., Esmy P.O., Poli U.R.R., Joshi G., Verma Y., Zomawia E., Shastri S.S., Pimple S., Anantharaman D., Prabhu P.R., Hingmire S., Sauvaget C., Lucas E., Pawlita M., Gheit T., Jayant K., Malvi S.G., Siddiqi M., Michel A., Butt J., Sankaran S., Rameshwari Ammal Kannan T.P., Varghese R., Divate U., Willhauck-Fleckenstein M., Waterboer T., Muller M., Sehr P., Vashist S., Mishra G., Jadhav R., Thorat R., Tommasino M., Pillai M.R., Sankaranarayanan R.; Indian HPV vaccine study group. Papillomavirus Res. 2019 Jan 31. pii: S2405-8521(18)30133-2.|